European Biopharmaceutical Review |
 |
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR. |
 |
| |
|
|
| In her Editor's Letter, Dr Helen Abbott gives us a brief synopsis of the range and content of this issue |
|
|
|
| Neal Ransome, Partner at PricewaterhouseCoopers, examines how Capital Markets Slowdown Triggers Pharma Micro-Deals in 2002 |
|
|
| Inadequate publicity and financing can hold biotech companies back. Biotech Companies in the Pharma Market - Grow or be Doomed, warns Dr Volker Janssen, Director at Simon-Kucher & Partners |
|
|
| In Partners With Vision - A Discussion on the Future of Pharma, William Powlett Smith, Audit Partner and Leader of UK Health Sciences at Ernst & Young, explores the importance of a long-range vision to pharmaceutical industry development |
|
|
| Dr Peter Seufer-Wasserthal, Vice President of Business Development at Morphochem AG, takes us From Platform to Product - Delivering the Pipelines of Tomorrow |
|
|
|
|
| Kelvin Stott and Andrew J Doig at Senexis Limited, explore the potential of Meptides: A Novel Class of Synthetic Peptide Derivatives for the Potential Treatment of Neurodegenerative Diseases |
|
|
| Mass spectrometry is widely viewed as the preferred analytical technique in proteomics research. Dr Chris Sutton, Global Business Manager with Kratos Analytical, considers its popularity, in MALDI-TOF - The Technique of Choice in Proteomics |
|
|
| Drug discovery requires millions of parallel biological tests on a miniature scale. In Catching the Code, Dr Ciaran Sewter, Dr Mark Evans and Dr Elizabeth Hill at 3D Molecular Sciences Ltd, suggest one possible approach |
|
|
|
| G Steven Burrill, CEO of Burrill & Company, examines the trend of pharmacogenomic testing, in From Pipe Dream to Pipeline Dream: Personalised Medicine Takes Off |
|
|
| In conversation with biotechnology reporter Allison Connolly, Dr Jeffrey Ross of Millennium Pharmaceuticals discusses Molecular Medicine: Targeting Patients with the Right Treatment |
|
|
| Inhalation is an effective but potentially hazardous method of drug delivery. Dr Colin J Hardy, Director of Inhalation Studies at Huntingdon Life Sciences investigates, in Assessing the Safety of Inhaled Biopharmaceuticals - Current Issues and Recent Developments |
|
|
| Sonja Lenz, Klaus Kellings and Helga Siakkou at NewLab BioQuality AG, look at Variant Creutzfeldt-Jakob Disease: Safety of Blood and Plasma Products |
|
|
|
| In Bioprospecting: Beyond Intellectual Property Rights - the Indigenous Challenge, Hayley French and Helen Cline at Taylor Wessing, discuss the issue of collecting biological samples |
|
|
| Dr Armin Bohmann, Founder and Partner of Bohmann & Loosen, and Dr Ulrich Gerth, Vice President of Equity Corporate Finance at Hypovereinsbank Corporates & Markets, highlight The Importance of Provisional Protection for Biotech Inventions |
|
|
| Brian Cain, Solicitor with Richards Butler, considers recent developments in the area of Utility, Inventiveness and Patenting DNA |
|
|
| In the concluding part of our two-part series, Absolute or Limited Product Protection for Biotech Inventions, Dr Uta Koster, Associate with Bardehle Pagenberg, analyses the various national laws and regulations within the EC and US |
|
|
|
| The advantages of the Medicon Valley biotech cluster are outlined in Biotech's Northern Alliance Gaining Ground: a report by Hal Grey, freelance journalist writing for Position SkЊne and Copenhagen Capacity |
|
|
|
| Dr Frank E Jones, Dr Matthew E Burow and Dr Steven M Hill of Tulane Cancer Center discuss Signal Transduction in Breast Cancer: Silencing the Cross-Talk |
|
|
| In The Development of PARP Inhibitors to Treat Cancer and Other Diseases, Professor Stephen P Jackson, Founder of KuDOS Pharmaceuticals Ltd, investigates the use of enzymes for DNA damage detection, signalling and repair |
|
|
| Dr Ramachandran Murali, Assistant Professor in the Department of Pathology and Laboratory of Medicine at the University of Pennsylvania, describes SPR Analysis of Rationally Designed Anti-HER2 Exocyclic Mimetics of Antibodies |
|
|
|
| In Large-Scale, Comprehensive Quality Control and Analysis of High-Throughput Screening Data, Swen Reimann, Michael Lindemann, Bernd Rinn, Olivier Lefèvre and Stephan Heyse at GeneData AG, suggest ways to get the most from HTS |
|
|
| Dr Jens Beator of Schleicher & Schuell BioScience, outlines approaches for proteome research, in From Protein Microarrays to Cytokine Detection Chips |
|
|
| Dr Richard Philpott, Managing Director of Acumen Bioscience Ltd, introduces Live Cells as Drug Discovery Tools - High-Throughput, High-Content Screening |
|
|
| Dr Robert Jones at Cambridge Consultants discusses the advantages and limitations of Surface Plasmon Resonance Applied to the High-Throughput Measurement of Molecular Binding |
|
|
| In Robotics in Pharmaceutical Research, David N Sands, CEO and Founder of ST Robotics International, describes some of the applications for the pharmaceutical industry |
|
|
| Dr Morten Bryhn, Director of R&D at Pronova Biocare, demonstrates the value of Omega-3 Fatty Acids in the Prevention of Myocardial Infarction |
|
|
| Gareth Davies, Operations Director at CEL International, highlights issues to be considered to get the best performance from a "fast track" project, in Fast Track Project Implementation: Risk or Reward? |
|
|
|
| What is biosaxony and how does it differ from the many other bio-locations? Dr Ivan Baines, Partner at Biopolis Consultants, introduces us to The biosaxony Region |
|
|
| In The Meuse-Rhine Triangle, Stafford Wadsworth, Editor and Publisher of the Meuse-Rhine Journal, explores the potential of this fast-growing Euroregion |
|
|
|
| In Where to Biomanufacture? One State's Efforts to Answer the Question, Barry D Teater, Director of Corporate Communications at the North Carolina Biotechnology Center, discusses biomanufacturing opportunities in North Carolina |
|
|
|
| Dr Keith Chidwick, Consultant at Technomark Consulting Services, reports from the recent Biotech Manufacturing 2003 conference in Amsterdam |
|
|
| CORDIA - EuropaBio* Convention 2003 is Europe's brand new life science convention. Launching in Vienna at the end of 2003, CORDIA is not simply a conference, nor is it purely an exhibition; its sole purpose is to provide a platform to stimulate the growth of the European biotechnology industry. |
|
|
|
|
|
